MedTrace Logo

A Combination of Abraxane and Cisplatin in Metastatic Breast Cancer

NCT01149798 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2012-08-07

No results posted yet for this study

Summary

This phase II trial on the assumption that abraxane and cisplatin combination therapy is efficacy in metastatic breast cancer.

Conditions

Interventions

DRUG

Abraxane and Cisplatin combination

Abraxane will be given at 125 mg/m2, venous infusion within 30 minutes, administered on days 1, 8 and 15. Cisplatin at 75mg/m2, venous infusion for 120 minutes, will be administered on day 1.

Sponsors & Collaborators

  • Fudan University

    lead OTHER

Principal Investigators

  • Xichun Hu · Fudan University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-30
Primary Completion
2011-06-30
Completion
2011-11-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01149798 on ClinicalTrials.gov